The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience
Introduction Direct antiviral agents (DAA) have made HCV treatment very effective and safe these last years. Recently, concerns were raised of high rates of HCC recurrence in patients treated with DAA. We investigated the HCC occurrence and recurrence rates within six months after treatment with DAA with or without Pegylated Interferon (PEG-IFN). Methods and materials This is a national, retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Data were available from two earlier trials investigating the outcome of treatment with DAA with and without PEG-IF... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | conferenceObject |
Erscheinungsdatum: | 2017 |
Schlagwörter: | Hepatitis C / direct acting antiviral therapy / hepatocellular carcinoma |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27305000 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/1942/23092 |